Sources listed
Methylene blue is a blue dye that hospitals keep on hand for one emergency: blood that has stopped carrying oxygen.[110] That is where most people's knowledge of it ends, and the studies go a lot further. In a randomized study of 80 people in hospital with severe COVID, those given methylene blue by mouth had better blood oxygen and shorter stays.[1] In Mali, adding it to the standard malaria drugs nearly eliminated the spread of malaria from people to mosquitoes by day 2.[16] In a randomized human study, a low dose by mouth raised brain activity during attention and memory tasks, and recall improved.[36] This is the long read. The human studies come first, COVID, malaria, the brain and pain, including the ones that found nothing. Then stroke and the pathogens, where the work is in animals and in the dish. Then how one dye does all of it, the one caution the maker prints, and what a bottle has to show you. Every claim carries its study, and each line says whether it was people, animals or a dish.
What did the COVID studies find?
Five human studies are in the library, and they do not all point the same way. In the randomized one, 80 people in hospital with severe COVID got standard care or standard care plus methylene blue by mouth. The methylene blue group had better blood oxygen and breathing rates and shorter hospital stays.[1] In a hospital cohort of 362 people with severe COVID, those given methylene blue by vein for 5 days on top of standard therapy had fewer deaths, shorter stays and less need for a ventilator.[2] Seven outpatients with severe COVID who took it by mouth with standard care all recovered, in a case series with no comparison group.[3]
Two human studies found no benefit. In a randomized, placebo-controlled study of 19 people with early COVID, methylene blue at 200 mg a day did not clear the virus faster than placebo.[4] In a retrospective cohort of hospitalized COVID patients, those given methylene blue by vein on top of standard care stayed longer, a median of 9 days against 5.[5]
The lab work explains why anyone tested it. In a cell-free test, methylene blue blocked the spike protein from locking onto its ACE2 receptor at about 3 micromolar and blocked a test virus from entering cells.[6] Two more labs measured the same block.[7][8] In monkey kidney cells it inhibited SARS-CoV-2 at a lower concentration than hydroxychloroquine or azithromycin in the same assay.[9] With low-dose red light it cut bovine coronavirus at least 10,000-fold in cell culture,[10] and with light it inhibited SARS-CoV-2 replication in the studies one review gathered.[11] Blood services already use methylene blue to inactivate pathogens in donated plasma.[12] A narrative review of the dish, animal and clinical reports found less infection and fewer deaths with methylene blue in the COVID studies it covered.[13] Early in the pandemic a hypothesis paper proposed the idea on other grounds, that methylene blue would block the nitric oxide effects of bradykinin, and called for clinical studies.[14]
One more virus has a human result. In a randomized study of 60 people with recurring cold sores, methylene blue with light reduced pain against acyclovir cream, and healing took about 3.2 days.[15]
Does methylene blue work against malaria?
The randomized studies in children and adults in West Africa are the strongest human evidence in this whole record.
- Mali, randomized: methylene blue added to the standard malaria drugs for 3 days nearly eliminated the spread of malaria from people to mosquitoes by day 2.[16]
- Burkina Faso, 180 children, randomized: 95% had an adequate response at day 28 on methylene blue with amodiaquine, against 82% on the standard pair. Vomiting was more common with methylene blue.[17]
- The same 180 children: the methylene blue groups carried significantly fewer gametocytes, the parasite form that infects mosquitoes.[18]
- Burkina Faso, 221 children, randomized: adding methylene blue to the standard pair meant fewer children carrying gametocytes on day 7, with lower hemoglobin and more vomiting.[19]
- Burkina Faso, randomized against primaquine: methylene blue with artesunate-amodiaquine was not shown equal to primaquine for hemoglobin recovery. The study was funded by BASF.[20]
- Healthy volunteers: adding methylene blue to artesunate-amodiaquine raised blood levels of the active artemisinin compound and strengthened the blood's activity against artemisinin-resistant parasites.[21]
In the lab the picture is consistent. Incubated with Plasmodium vivax parasites taken from patients, methylene blue cut the infection passed to mosquitoes about 1,438-fold,[22] and it fully blocked that spread at 20 micromolar in a second study.[23] In the dish it deformed or eliminated the gametocytes of Plasmodium falciparum,[24] and, like primaquine, it sterilized them before their numbers fell.[25] It was highly active against drug-resistant falciparum and vivax parasites from patients in Papua, Indonesia,[26] and it kept working against the early stage of artemisinin-resistant parasites at very low concentrations.[27] In the dish it worked together with the artemisinin drugs and against chloroquine.[28] In lab and mouse experiments it was active against the blood stage of the parasite, the youngest forms most of all,[29] and a related bacterial pigment that also worked in the dish proved too toxic in mice, where methylene blue was not.[30] In rats and monkeys with malaria, methylene blue by vein did about as well as artesunate by vein, and the two together did better than either.[31] One other parasite has a result: with light, methylene blue and its relatives cut the dose needed against Leishmania by up to 85% in the dish.[32]
Other parasites have lab and animal results only. In the dish, methylene blue and its relatives inhibited Leishmania at very low concentrations,[33] and with red light it worked on a strain resistant to the drug miltefosine.[34] In mice infected with the parasite Neospora, methylene blue with a related dye did better than a standard drug regimen.[35]
What does methylene blue do in the brain?
The human brain studies used a single low dose by mouth and a scanner. In one randomized study, methylene blue raised brain activity during sustained attention and short-term memory tasks, and memory recall improved.[36] In a second, a randomized, double-blind, placebo-controlled study of 28 healthy adults, a single 280 mg dose lowered task-related blood flow in the brain and strengthened the resting connections between regions that handle perception and memory.[37]
Two randomized studies gave it during surgery. One dose during the operation cut delirium in older patients from 24% to 7%, with a lower blood marker of nerve cell injury.[38] In 217 older patients having a joint replaced, delirium followed in 8.3% with methylene blue and 20.4% without, and fever after surgery was more common with it.[39] Pooled, three randomized studies in 779 surgical patients found the odds of delirium cut by about two thirds with methylene blue by vein during the operation.[40]
In a randomized crossover study of adults with bipolar disorder taking lamotrigine, methylene blue lowered residual depression and anxiety scores.[41] A brain imaging study found that people with bipolar disorder responded to methylene blue by vein with larger drops in oxygen metabolism in the front of the brain than healthy people did.[42]
For mood and fear the human work is the bipolar studies. A review of them reports antidepressant and anti-anxiety effects with no switch into mania.[43] In rats, a low dose after fear-extinction training reduced the return of fear only in the animals that had responded to the training.[44] In mice, a dose given first blocked most of the depression-like behavior and memory deficits that a bacterial toxin causes.[45]
A related compound, hydromethylthionine, has been through large studies in Alzheimer's disease and a related dementia. The five human studies and analyses here were funded by the company that develops it, and each is marked. In its phase 3 study of 598 people, it did not separate from the low-dose control on the main 52-week measures, while blood markers of nerve cell loss came down (industry funded).[46] In an earlier phase 3 study in mild Alzheimer's disease the randomized comparison showed no difference, and a non-randomized look at people taking the low dose alone found better thinking, function and MRI results (industry funded).[47] In 220 people with frontotemporal dementia, 200 mg a day did no better than 8 mg a day as randomized, and a blood-level analysis found the effect on decline and brain shrinkage tracked concentration at the low dose (industry funded).[48]
- An industry-funded analysis of 1,162 patients from two Alzheimer's studies linked higher blood levels at 8 mg a day to less cognitive decline and less brain shrinkage.[49]
- Modelling of 710 participants found the body clears the compound in a U-shaped pattern over long dosing, which the authors give as the reason the low-dose control was active.[50]
- Set against matched outside controls, 16 mg a day went with slower cognitive decline and less brain shrinkage (funded by TauRx Therapeutics).[51]
- A dosing study in people and animals found that how the compound dissolves in the stomach, and whether food is present, changed how much was absorbed.[52]
- In mice, it reversed a drug-induced learning deficit,[53] and in a tau mouse model it lowered a damaged form of tau and the inflammatory signal TNF-alpha for at least 12 weeks after dosing stopped.[54]
- In the lab, the oxidized form of the compound drove bonds to form between two points on the tau protein, using oxygen.[55]
Does methylene blue help with pain?
Four human results. Across 6 studies and 432 cancer patients with mouth sores from chemotherapy and radiation, methylene blue, as a mouth rinse or with laser, cut pain by 4.81 points on a 10 point scale.[56] In a separate open-label study of 43 hospitalized cancer patients, a 0.05% methylene blue mouthwash for three days lowered pain about as much as the standard mouthwash.[57] Across 6 randomized studies and 598 patients, methylene blue after hemorrhoid surgery meant lower pain scores for seven days and fewer people needing painkillers, with no more complications.[58] In a randomized study of adults with painful urination, methenamine with 20 mg of methylene blue gave more people an excellent response within 24 hours than phenazopyridine did. The study was funded by EMS S.A.[59]
In a randomized study of 58 patients having bone taken from the hip, methylene blue added to the local anesthetic meant lower pain from 12 hours to day 5, and 4.5 days of disturbed walking against 11.[60] In 281 cancer patients with mouth sores, pain fell from 7.7 to 2.5 out of 10 after a methylene blue rinse, in a look back with no comparison group.[61] In 60 children aged 3 to 6 having a tooth nerve removed, methylene blue with light lowered pain for 72 hours against a sham laser, and not at one week.[62] One comparison went the other way: in 150 patients after hemorrhoid surgery, a long-acting local anesthetic gave lower pain scores than a methylene blue mix.[63]
What did methylene blue do in stroke and brain injury?
This work is in animals. Mice given methylene blue before a stroke had a damaged area 57.1% smaller.[64] In rats with a blocked brain artery, it shrank the damaged area and improved their neurological scores,[65] and with extra oxygen it sped the recovery of movement, a gain that held to day 28.[66] Given after blood flow returned, it reduced the brain swelling.[67] In rats with a mild traumatic brain injury it meant smaller lesions on MRI, better limb function and fewer dying neurons,[68] and in mice it partly reduced the memory deficits after such an injury.[69] After a crush injury to the optic nerve it preserved the retina's electrical responses and more of its nerve cells,[70] and after the nerve was cut, methylene blue in the eye left more of those cells alive and regrowing.[71] In rats pushed through exhaustive exercise, methylene blue by nose kept their memory and their hippocampus intact.[72] A review lists it among the agents that restore ATP production and reduce brain damage when blood flow is cut.[73]
Timing mattered in the heart. In rats, methylene blue given before blood flow to the heart was cut raised dangerous rhythms and deaths. Given after the cut and before flow returned, it lowered them.[74]
Does methylene blue kill bacteria and fungi?
Most of this work pairs it with light, in the dish. Methylene blue, light and a plasma discharge killed up to 99.998% of Staphylococcus aureus, a 4.8 log cut.[75] With 660 nm red light it shut down the biofilms that Streptococcus mutans and Candida albicans build to hide in.[76] With light it reduced Enterococcus faecalis in a root canal model[77] and Pseudomonas aeruginosa colonies.[78] In people, 21 with diabetic foot ulcers got methylene blue and laser light on top of standard care and their wound scores improved,[79] and in nail fungus, methylene blue with light cleared 90% of cases clinically, ahead of fluconazole.[80]
Three studies used it with no light. With no light, methylene blue at 16 micrograms per ml and up killed MRSA in the dish, and in 2 of 10 samples it worked together with the antibiotic cefoxitin.[81] In the dish, methylene blue at 0.05% and 0.1% cut the growth of Staphylococcus hominis and Acinetobacter baumannii.[82] In mice infected with Mycobacterium ulcerans, purified methylene blue on the skin or by injection lowered the clinical scores, and the two together cut the bacterial density most.[83] A lab-method study found that a culture plate made with methylene blue held back about 35% of colistin-resistant Acinetobacter baumannii samples.[84]
More results in people, all with light. In a randomized study in diabetic foot ulcers, red laser with 1% methylene blue on top of care improved wound scores.[85] In 18 people with oral thrush, methylene blue with light and nystatin lozenges showed no significant difference.[86] In 50 orthodontic patients, adding it to a cleaning gave no extra gain in gum inflammation at 3 months.[87] Across 13 animal studies it favored the healing of infected skin wounds.[88]
Helicobacter pylori has lab results only. With 660 nm light, methylene blue eliminated the free-swimming bacteria in the dish, its biofilms resisted, and the infection came back in piglets.[89] Chitosan given first raised the kill about 10 million-fold.[90]
Why do intensive care units use methylene blue in septic shock?
For blood pressure, not for the infection, and this is now the best-studied use in people after malaria. In a randomized study of 91 people in septic shock, those given methylene blue early came off blood pressure drugs sooner than the placebo group.[91] In a double-blind randomized study of 90 cancer patients in septic shock, a low dose and a high dose both shortened the time on blood pressure drugs against placebo, and the two doses did the same.[92] In a randomized study of 72 patients, methylene blue improved blood flow in the smallest vessels against saline, while 28-day deaths and days free of organ support were not significantly different.[93] Two small randomized studies, 15 and 20 patients, found higher blood pressure and less need for blood pressure drugs, and in the dose-finding one the highest doses raised a concern about blood flow to the gut.[94][95]
Pooled, 11 randomized studies in 556 critically ill and surgical patients found a 40% lower risk of death with methylene blue, shorter stays and higher blood pressure.[96] Two pooled analyses of septic shock alone, 5 randomized studies with 257 adults and 6 with 302, found fewer deaths and shorter hospital stays, on evidence their authors grade as low certainty.[97][98] A pooled analysis of 15 studies and 832 patients in shock found fewer deaths, less need for blood pressure drugs and less kidney failure.[99] Three randomized studies with 141 patients found shorter intensive care stays, fewer days on a ventilator and a faster end to blood pressure drugs.[100]
Three results point the other way or stop short. In a two-hospital look back at 303 patients whose shock would not respond, methylene blue and hydroxocobalamin lowered the need for blood pressure drugs about equally, and more of the methylene blue group died in hospital.[101] A pooled look at 24 mostly case-report studies found higher blood pressure at one hour with hydroxocobalamin than with methylene blue.[102] An earlier systematic review found higher blood pressure and less need for blood pressure drugs, and said deaths had not been measured well enough to judge.[103]
The reviews written in Portuguese and Spanish read the same way. A systematic review of 9 studies found better blood vessel tone, less need for blood pressure drugs and shorter stays with methylene blue in septic shock, and no consistent drop in deaths.[104] A second review found shorter use of blood pressure drugs and higher arterial pressure in shock that had stopped responding.[105] A scoping review of 6 studies concluded that giving it early went with a better course and better survival.[106] In 20 patients with shock that would not respond, 45% responded to a dose of methylene blue.[107] In mice, methylene blue with vitamin B12 before septic shock lowered the inflammatory markers.[108]
How does one blue dye do that? Start with oxygen.
In the blood. Some poisons and drugs change hemoglobin into a form that cannot carry oxygen. The person turns blue, and extra oxygen does nothing. A 32-year-old woman who swallowed a product containing nitrobenzene was reversed fast with methylene blue by vein.[109] A 3-year-old who arrived blue and unresponsive to oxygen recovered completely.[110] The same reversal is on record in a preterm infant[111] and in an 80-year-old.[112] A historical review calls it the first-line antidote for this, one to keep on hand in emergency and critical care.[113]
In the cell. Your mitochondria make energy by handing electrons down a line to oxygen. Methylene blue carries electrons along that line.[114] When the first step of the line was blocked in mouse liver cells, methylene blue carried the electrons around the block and the cells lived.[115] In cultured cells it raised mitochondrial capacity.[116] In brain cells starved of oxygen and sugar, it raised sugar uptake and ATP and the cells survived.[117] The picture inside the mitochondria is not one-directional: in isolated rat brain mitochondria, methylene blue raised the activity of the first step of the energy line, lowered the last, and at low doses raised electron leak.[118] By mouth it is well absorbed: in 16 healthy volunteers about 72% of a dose reached the blood.[119] That is the thread running through the stroke, brain injury and poisoning results above: a cell that can still turn oxygen into energy.
With light. Light switches methylene blue on. It hands energy to oxygen, and that reactive oxygen breaks DNA, in lab cells.[120] Aimed at a microbe, that is the kill in the bacteria and virus studies above. It also turns inflammation down in animals: in mice with allergic airways there was less lung damage, less oxidative stress, fewer inflammatory cells and less of the allergy antibody IgE, and more of it did more.[121] In brain disease models it lowered inflammation along with oxidative stress.[122]
On cancer cells the work is in animals and the dish, with light. In a systematic review of 10 mouse studies, methylene blue with light shrank tumors in 7.[123]
Who should not combine methylene blue with their medication?
One caution, and it is the one the maker prints. The listing for the bottle I read says methylene blue has MAO-inhibitor properties, and "do not combine with SSRIs, anti-depressants, or other serotonin-affecting substances without medical supervision." Serotonin syndrome is why. It is on record in a cancer patient who was already on serotonin-active medication,[124] and in a 95-year-old woman after ondansetron was added.[125] A review gathered 50 cases, and every one of them was taking a serotonin-acting antidepressant.[126] A systematic review found that 24 of 26 patients who became acutely confused after methylene blue by vein were taking a serotonin reuptake inhibitor.[127]
Why does the maker matter?
Methylene blue is a manufactured dye, so the grade, the dose and the test results are the product. The label should print USP grade and the milligrams in one ml. Ask any maker for the certificate of analysis: the measured dose, heavy metals and microbes for that batch. No USP grade on the label and no certificate of analysis means do not buy it.
Plastic is the other half. One liter of bottled water carried about 240,000 plastic fragments.[128] In a randomized study, a plasticizer showed up in volunteers' urine after blood stored in plasticizer-free bags, because the tubing still carried it.[129] So this is what I looked for when I walked the Global Healing lab in Houston. No plastic touches the water: it runs through platinum and silicone tubing, and extraction is in glass. They test for pesticides, mold and residual chemicals, the things a dose number alone will not show. The label, the certificate of analysis and the price of the bottle I read are on the methylene blue page.
Key Takeaways
- In a randomized study of 80 people hospitalized with severe COVID, methylene blue by mouth meant better blood oxygen and shorter stays; a 362-patient cohort found fewer deaths; two smaller human studies found no benefit.
- Randomized studies in Mali and Burkina Faso are the strongest human evidence: the spread of malaria to mosquitoes nearly eliminated by day 2, and a 95% response at day 28 against 82%.
- A low dose by mouth raised human brain activity and recall in a randomized study, and one dose during surgery cut delirium in older patients in two randomized studies.
- In septic shock, randomized studies found people came off blood pressure drugs sooner with methylene blue, and 11 pooled randomized studies in critically ill and surgical patients found a 40% lower risk of death; one hospital comparison found more deaths with it.
- The stroke, brain injury, H. pylori, MRSA, other-parasite and cancer-cell results are from animals and the dish, and each line above says which.
- It works with oxygen in two places: it puts hemoglobin back to work in the blood, and it carries electrons along the line mitochondria use to make energy.
- Do not combine it with SSRIs, anti-depressants or other serotonin-affecting substances without medical supervision. Ask any maker for USP grade and a certificate of analysis.
Sources
Powered by CellWell- 1.Methylene blue for treatment of hospitalized COVID-19 patients: a randomized, controlled, open-label clinical trial, phase 2 (2021)
- 2.Methylene Blue in Treatment of Severe COVID-19 Patients: A Large Cohort Study (2024)
- 3.Treatment of Severe COVID-19 Outpatients by Methylene Blue (First Report) (2022)
- 4.Evaluation of the Efficacy of Methylene Blue Administration in SARS-CoV-2-Affected Patients: A Proof-of-Concept Phase 2, Randomized, Placebo-Controlled, Single-Blind Clinical Trial (2024)
- 5.Clinical Outcomes of Parenteral Methylene Blue as Adjunct Therapy in Hospitalized COVID-19 Patients: A Retrospective Cohort Study (2026)
- 6.Methylene Blue Inhibits the SARS-CoV-2 Spike–ACE2 Protein-Protein Interaction–a Mechanism that can Contribute to its Antiviral Activity Against COVID-19 (2021)
- 7.A Drug Repurposing Approach for Antimalarials Interfering with SARS-CoV-2 Spike Protein Receptor Binding Domain (RBD) and Human Angiotensin-Converting Enzyme 2 (ACE2) (2021)
- 8.Methylene Blue Is a Nonspecific Protein–Protein Interaction Inhibitor with Potential for Repurposing as an Antiviral for COVID-19 (2022)
- 9.Methylene blue inhibits replication of SARS-CoV-2 in vitro (2020)
- 10.Infectivity and Morphology of Bovine Coronavirus Inactivated In Vitro by Cationic Photosensitizers (2022)
- 11.Photodynamic Action of Curcumin and Methylene Blue against Bacteria and SARS-CoV-2—A Review (2023)
- 12.Apport de la protéomique à la médecine transfusionnelle : étude de l’impact des traitements d’inactivation des agents pathogènes et des conditions de stockage sur les protéines plasmatiques (2026)
- 13.Application of methylene blue for the prevention and treatment of COVID-19: A narrative review (2024)
- 14.Methylene blue may have a role in the treatment of COVID-19 (2020)
- 15.Effect of combined antimicrobial photodynamic therapy and photobiomodulation therapy in the management of recurrent herpes labialis: a randomized controlled trial (2025)
- 16.Efficacy and safety of primaquine and methylene blue for prevention of Plasmodium falciparum transmission in Mali: a phase 2, single-blind, randomised controlled trial (2018)
- 17.Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso (2008)
- 18.Strong gametocytocidal effect of methylene blue-based combination therapy against falciparum malaria: a randomised controlled trial (2009)
- 19.Efficacy and safety of triple combination therapy with artesunate-amodiaquine-methylene blue for falciparum malaria in children: a randomized controlled trial in Burkina Faso (2015)
- 20.Safety and efficacy of artesunate-amodiaquine combined with either methylene blue or primaquine in children with falciparum malaria in Burkina Faso: A randomized controlled trial (2019)
- 21.Pharmacokinetics and Ex Vivo Antimalarial Activity of Artesunate-Amodiaquine plus Methylene Blue in Healthy Volunteers (2020)
- 22.Transmission-blocking activities of artesunate, chloroquine, and methylene blue on Plasmodium vivax gametocytes (2024)
- 23.The activity of methylene blue against asexual and sexual stages of Plasmodium vivax (2023)
- 24.Methylene blue induced morphological deformations in Plasmodium falciparum gametocytes: implications for transmission-blocking (2018)
- 25.Transmission-blocking Effects of Primaquine and Methylene Blue Suggest Plasmodium falciparum Gametocyte Sterilization Rather Than Effects on Sex Ratio (2019)
- 26.Potent Ex Vivo Activity of Naphthoquine and Methylene Blue against Drug-Resistant Clinical Isolates of Plasmodium falciparum and Plasmodium vivax (2015)
- 27.Methylene blue retains in vitro activity against early ring-stage artemisinin-resistant Plasmodium falciparum (2026)
- 28.In vitro assessment of methylene blue on chloroquine-sensitive and -resistant Plasmodium falciparum strains reveals synergistic action with artemisinins (2005)
- 29.Etude pharmacologique expérimentale de l'activité antipaludique d'un composé de synthèse: le chlorure de methylthioninium (2007)
- 30.The bacterial redox signaller pyocyanin as an antiplasmodial agent: comparisons with its thioanalog methylene blue (2011)
- 31.Efficacy of intravenous methylene blue, intravenous artesunate, and their combination in preclinical models of malaria (2014)
- 32.Light, Dyes, and Action: Photodynamic Inactivation of Leishmania amazonensis Using Methylene Blue, New Methylene Blue, and Novel Ruthenium-Based Derivatives (2025)
- 33.From Dyes to Drugs? Selective Leishmanicidal Efficacy of Repositioned Methylene Blue and Its Derivatives in In Vitro Evaluation (2025)
- 34.Photodynamic therapy mediated by a red LED and methylene blue inactivates resistant Leishmania amazonensis (2023)
- 35.Inhibitory action of phenothiazinium dyes against Neospora caninum (2020)
- 36.Multimodal Randomized Functional MR Imaging of the Effects of Methylene Blue in the Human Brain (2016)
- 37.Methylene blue modulates functional connectivity in the human brain (2017)
- 38.Methylene Blue for Prevention of Perioperative Neurocognitive Disorders: Mechanisms and Recent Clinical Evidence (2026)
- 39.Effect of intraoperative methylene blue on postoperative delirium in elderly patients undergoing joint replacement: a randomized controlled trial (2025)
- 40.Intraoperative methylene blue administration and postoperative delirium: a meta-analysis of surgical patients (2026)
- 41.Methylene blue treatment for residual symptoms of bipolar disorder: randomised crossover study (2017)
- 42.Altered oxidative neurometabolic response to methylene blue in bipolar disorder revealed by quantitative neuroimaging (2024)
- 43.Methylene Blue in the Treatment of Neuropsychiatric Disorders (2019)
- 44.Preventing the return of fear using reconsolidation updating and methylene blue is differentially dependent on extinction learning (2017)
- 45.Methylene blue exerts rapid neuroprotective effects on lipopolysaccharide-induced behavioral deficits in mice (2019)
- 46.Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer's disease (2026)
- 47.Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial (2018)
- 48.Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia (2020)
- 49.Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer's Disease (2019)
- 50.Atypical population pharmacokinetics of hydromethylthionine in patients with Alzheimer's disease explains unexpected phase 3 trial results (2026)
- 51.Assessment of clinical and neuroimaging efficacy of treatment targeting tau pathology in mild cognitive impairment and mild to moderate Alzheimer's disease with hydromethylthionine mesylate using external control data (2026)
- 52.Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer's disease (2015)
- 53.Effects of hydromethylthionine mesylate and rivastigmine in a pharmacological mouse model of Alzheimer's disease (2026)
- 54.Hydromethylthionine sustains truncated tau-dependent inflammation-lowering effects in mouse brain (2025)
- 55.Mechanism of Methylene Blue Inducing the Disulfide Bond Formation of Tubulin-Associated Unit Proteins (2024)
- 56.Methylene blue in chemoradiotherapy-induced oral mucositis: Systematic review and meta-analysis (2026)
- 57.Methylene Blue Mouthwash for Oral Mucositis Pain in Cancer: An Open-Label, Non-Randomized Study (2026)
- 58.Efficacy and safety of methylene blue for postoperative pain of haemorrhoids: a systematic review and meta-analysis (2025)
- 59.Efficacy of methenamine with methylthioninium in the treatment of dysuria: a randomized clinical study (2023)
- 60.Methylene Blue Injection for Pain Reduction at Iliac Crest Donor Sites: A Randomized Trial and Meta-analysis (2026)
- 61.Methylene Blue for the Treatment of Intractable Pain From Oral Mucositis Related to Cancer Treatment: An Uncontrolled Cohort (2021)
- 62.Effect of photodynamic therapy on postoperative pain after pulpectomy in paediatric patients under general dental anaesthesia: A randomised controlled trial (2026)
- 63.Comparison of compound methylene blue (methylene blue + ropivacaine) and bupivacaine liposome for pain control after mixed hemorrhoid surgery: A comprehensive analysis based on clinical studies (2026)
- 64.Neuroprotection Against Ischemic Brain Injury with Methylene Blue (P1.104) (2014)
- 65.Methylene Blue Reduces Acute Cerebral Ischemic Injury via the Induction of Mitophagy (2015)
- 66.Methylene blue and normobaric hyperoxia combination therapy in experimental ischemic stroke (2016)
- 67.The protective effects of methylene blue on astrocytic swelling after cerebral ischemia-reperfusion injuries are mediated by Aquaporin-4 and metabotropic glutamate receptor 5 activation (2024)
- 68.Methylene blue is neuroprotective against mild traumatic brain injury (2014)
- 69.Methylene Blue Protects Spatial Working Memory after Traumatic Brain Injury in Mice by Affecting Mitochondrial Quality Control System (2025)
- 70.Neuroprotective Effect of Methylene Blue in a Rat Model of Traumatic Optic Neuropathy (2025)
- 71.Methylene blue promotes survival and GAP-43 expression of retinal ganglion cells after optic nerve transection (2020)
- 72.Intranasal methylene blue administration confers neuroprotection in rats subjected to exhaustive exercise training (2025)
- 73.Therapeutic modulation of energy metabolism in ischemic brain injury (2026)
- 74.Cardiotoxic and Cardioprotective Effects of Methylene Blue in the Animal Model of Cardiac Ischemia and Reperfusion (2024)
- 75.Cold atmospheric plasma degrades methylene blue and shifts bacterial inactivation during photodynamic therapy (2026)
- 76.Antimicrobial photodynamic therapy mediated by methylene blue-loaded polymeric micelles against Streptococcus mutans and Candida albicans biofilms (2023)
- 77.Synergistic Antimicrobial Effect of Photodynamic Inactivation and SWEEPS in Combined Treatment against Enterococcus faecalis in a Root Canal Biofilm Model: An In Vitro Study (2023)
- 78.Physiotherapeutic Intervention with Biofotododynamic Therapy for the Reduction of Pseudomonas Aeruginosa (2018)
- 79.Adjuvant effect of antimicrobial photodynamic therapy (aPDT) in the treatment of diabetic foot ulcers: A case series (2024)
- 80.Photodynamic therapy of onychomycosis: modern photosensitizers and clinical efficacy (literature review) (2026)
- 81.In Vitro and Ex Vivo Investigation of the Antibacterial Effects of Methylene Blue against Methicillin-Resistant Staphylococcus aureus (2024)
- 82.Antimicrobial effect of methylene blue in microbiologic culture to diagnose periprosthetic joint infection: an in vitro study (2022)
- 83.Effectiveness of purified methylene blue in an experimental model of Mycobacterium ulcerans infection (2017)
- 84.In vitro activity of methylene blue and eosin methylene blue agar on colistin-resistant A. baumannii: an experimental study (2019)
- 85.Antimicrobial photodynamic therapy improves wound quality and tissue repair in diabetic foot ulcers: A randomized double blind controlled clinical trial (2026)
- 86.Clinical feasibility of chairside methylene blue-mediated photodynamic therapy for oral candidiasis (2026)
- 87.Efficacy of mechanical debridement with adjunct antimicrobial photodynamic therapy for the management of plaque-induced gingivitis in patients undergoing clear aligner therapy and fixed orthodontic therapy (2026)
- 88.Antimicrobial photodynamic therapy with methylene blue and its derivatives in animal studies: Systematic review (2024)
- 89.Helicobacter pylori inhibition by antimicrobial photodynamic therapy of methylene blue and porphyrin (2026)
- 90.Synergistic in vitro photodynamic antimicrobial activity of methylene blue and chitosan against Helicobacter pylori 26695 (2014)
- 91.Early adjunctive methylene blue in patients with septic shock: a randomized controlled trial (2023)
- 92.Comparative study between high and low dose methylene blue infusion in septic cancer patients: a randomized, blinded, controlled study (2025)
- 93.The Effect of Methylene Blue on Sublingual Microcirculation in Patients with Septic Shock: A Randomized Controlled Trial (2025)
- 94.A dose-finding study of methylene blue to inhibit nitric oxide actions in the hemodynamics of human septic shock (2010)
- 95.Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study (2001)
- 96.Methylene Blue Reduces Mortality in Critically Ill and Perioperative Patients: A Meta-Analysis of Randomized Trials (2024)
- 97.The use of methylene blue in adult patients with septic shock: a systematic review and meta-analysis (2025)
- 98.Methylene Blue in Septic Shock: A Systematic Review and Meta-Analysis (2024)
- 99.Efficacy and safety of methylene blue in patients with vasodilatory shock: A systematic review and meta-analysis (2022)
- 100.Methylene blue in sepsis and septic shock: a systematic review and meta-analysis (2024)
- 101.A two-center comparison of the efficacy of methylene blue and hydroxocobalamin for the treatment of refractory shock (2026)
- 102.Hydroxocobalamin for Vasodilatory Hypotension in Shock: A Systematic Review With Meta-Analysis for Comparison to Methylene Blue (2023)
- 103.Use of methylene blue in sepsis: a systematic review (2006)
- 104.Azul de metileno como terapia adjuvante no tratamento de pacientes com choque séptico: uma revisão sistemática (2026)
- 105.Azul de metileno no choque séptico refratário: revisão integrativa das evidências sobre eficácia hemodinâmica e impacto clínico methylene blue in refractory septic shock: an integrative review of the evidence on hemodynamic efficacy and clinical impact azul de metileno en el shock séptico refractario: una revisión integradora de la evidencia sobre la eficacia hemodinámica y el impacto clínico (2026)
- 106.Uso do azul de metileno na sepse e choque séptico: uma revisão de escopo (2025)
- 107.Methylene blue administration in patients with refractory distributive shock – a retrospective study (2020)
- 108.Vitamin B12 combined with methylene blue alleviates experimental septic shock and is associated with modulation of KCNMB1 and the cGMP-PRKG pathway (2026)
- 109.Acquired Methemoglobinemia Following Nitrobenzene Poisoning: An Unusual Case Report (2025)
- 110.Naphthalene-Induced Methemoglobinemia With Acute Hemolysis in a Child: A Rare Case of Refractory Hypoxia (2026)
- 111.Late-Onset Neonatal Cyanosis Secondary to Methemoglobinemia in a Preterm, Small-for-Gestational-Age Infant: A Case Report (2026)
- 112.Case Report: Methemoglobinemia associated with compound aminopyrine-phenacetin tablets supported by toxicological evidence (2026)
- 113.Azul de metileno: De tinte textil en la época victoriana a antídoto esencial en la metahemoglobinemia (2026)
- 114.Protection against neurodegeneration with low-dose methylene blue and near-infrared light (2015)
- 115.Bypassing the compromised mitochondrial electron transport with methylene blue alleviates efavirenz/isoniazid-induced oxidant stress and mitochondria-mediated cell death in mouse hepatocytes (2014)
- 116.Combining lipoic acid to methylene blue reduces the Warburg effect in CHO cells: From TCA cycle activation to enhancing monoclonal antibody production (2020)
- 117.Methylene blue-induced neuronal protective mechanism against hypoxia-reoxygenation stress (2015)
- 118.Methylene blue modulates mitochondrial electron flow via multiple regulatory sites in isolated brain mitochondria: Implications for neurodegeneration (2026)
- 119.High absolute bioavailability of methylene blue given as an aqueous oral formulation (2009)
- 120.Protective effects of fungal (1$rarr;3)-$beta;--glucan derivatives against oxidative DNA lesions in V79 hamster lung cells (2003)
- 121.Methylene blue attenuates ovalbumin-induced airway inflammation and oxidative stress in mouse model of asthma (2026)
- 122.Mitochondria as a target for neuroprotection: role of methylene blue and photobiomodulation (2020)
- 123.Methylene blue in anticancer photodynamic therapy: systematic review of preclinical studies (2023)
- 124.A Case study of polypharmacy-induced serotonin syndrome in a cancer patient (2024)
- 125.The Blue Delirium: Serotonin and Anticholinergic Toxicity in a 95-Year-Old Woman (2026)
- 126.Serotonin Toxicity and Urinary Analgesics: A Case Report and Systematic Literature Review of Methylene Blue-Induced Serotonin Syndrome (2018)
- 127.The role of methylene blue in serotonin syndrome: a systematic review (2010)
- 128.Rapid single-particle chemical imaging of nanoplastics by SRS microscopy (2024)
- 129.Urinary di-(2-ethylhexyl) phthalate metabolites for detecting transfusion of autologous blood stored in plasticizer-free bags (2016)
Related
Want the next one of these?
The Signal is one email when there is something genuinely worth your attention -- written the way this post is, in plain language, with the studies behind it. No noise, no selling your address, and nothing to buy.
The Signal, and nothing else -- no fixed schedule, only when there is something worth sending. We never sell or share your address, and you can unsubscribe in one click any time.